Study: Metronomic Chemotherapy in Dogs with Splenic Hemangiosarcoma
Location: Tufts University Cummings School of Veterinary Medicine, North Grafton, MA
Phone: Kelly Reed, Oncology Liaison; (508) 887-4682

Eligibility: Dogs with hemangiosarcoma that have completed a standard course of chemotherapy after removal of the
affected spleen.

Exclusion: Dogs with a life expectancy of less than 1 month or who have lower urinary tract disease are ineligible.

Summary: The goal of this study is to evaluate the efficacy of low dose of metronomic chemotherapy as a maintenance
therapy in dogs with hemangiosarcoma. Hemangiosarcoma is a common tumor developing in the spleen of dogs. Despite
aggressive treatment with surgery and chemotherapy, most dogs die of metastatic disease shortly after treatment
Metronomic (low dose chemotherapy) entails very small doses of chemotherapy that are given daily or every other day
and help deter the growth of new blood vessels needed to nourish cancer as it grows. Side effects associated with
metronomic chemotherapy tend to be milder and less frequent than those seen with standard chemotherapy. This form of
chemotherapy has been used in dogs with spenic hemangiosarcoma after surgery and has been found to have efficacy
as a single agent.

Requirement and incentive: This study is not funded; so pet owners are responsible for all costs associated with this
Comprehensive guide to cancer diagnosis and treatment in cats and dogs
© 2007 Pet Cancer Center. ALL RIGHTS RESERVED.
Last updated 8/16/13
Please take our short survey to help us understand pet owners' perception of clinical trials.
Clinical trials for spleen hemangiosarcoma in dogs
Open clinical
trials for dogs
Dog Fences Training and Bark Collars Pet Feeders
Find clinical trials for specific tumor types in dogs: